Edition:
United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

5.54USD
14 Dec 2017
Change (% chg)

$-0.58 (-9.48%)
Prev Close
$6.12
Open
$6.14
Day's High
$6.14
Day's Low
$5.51
Volume
200,064
Avg. Vol
260,314
52-wk High
$11.71
52-wk Low
$4.61

Chart for

About

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging... (more)

Overall

Beta: 3.41
Market Cap(Mil.): $389.30
Shares Outstanding(Mil.): 70.27
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Progenics Pharmaceuticals Q3 loss per share $0.22

* Progenics Pharmaceuticals announces third quarter 2017 financial results and business update

Nov 02 2017

BRIEF-Progenics Pharmaceuticals provides update on timing of NDA submission for Azedra

* Progenics Pharmaceuticals provides update on timing of NDA submission for Azedra

Aug 31 2017

BRIEF-Progenics Pharmaceuticals Q2 loss per share $0.24

* Progenics Pharmaceuticals announces second quarter 2017 financial results and business update

Aug 09 2017

Earnings vs. Estimates